Drug Trial Radar · NCT06538558
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Oct 16, 2024
Primary completion
Oct 14, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Proniras CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Indiana University
- First posted
- Aug 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is examining the use of Tezampanel (TZP) for treatment of Opioid Withdrawal Syndrome (OWS) in participants with Opioid Use Disorder (OUD). Participants will receive TZP or placebo (PBO) daily on Days 2 - 7 during a 7-day inpatient stay at the research center to determine safety, pharmacokinetic (PK) assessment, and efficacy of TZP for OWS.
Conditions
- Opioid Use Disorder
Interventions
TezampanelDrug
Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation
PlaceboDrug
Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate systemic tolerability and safety of intravenous tezampanel administration.Time frame: First Dose through Day 10 visit
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Indiana University School of Medicine
Indianapolis, Indiana · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.